All-cause hospitalization and associated costs in patients with schizophrenia or bipolar disorder initiating long-acting injectable antipsychotics

References

• Schizophrenia [Internet]. Bethesda, MD: The National Institute of Mental Health; 2016. Available online at: https://www.nimh.nih.gov/health/statistics/prevalence/schizophrenia.shtml. Accessed February 12, 2017
   Google Scholar
• Bipolar Disorder among Adults [Internet]. Bethesda, MD: The National Institute of Mental Health; 2016. Available online at: https://www.nimh.nih.gov/health/statistics/prevalence/bipolar-disorder-among-adults.shtml. Accessed February 12, 2017
   Google Scholar
• Barkhof E, Meijer CJ, de Sonneville LMJ, et al. Interventions to improve adherence to antipsychotic medication in patients with schizophrenia–a review of the past decade. Eur Psychiatry 2012;27:9-18
   PubMed Web of Science ®Google Scholar
• Durden E, Bagalman E, Muser E, et al. Characteristics, healthcare utilization and costs of bipolar disorder type I patients with and without frequent psychiatric intervention in a Medicaid population. J Med Econ 2010;13:698-704
   PubMedGoogle Scholar
• Cloutier M, Aigbogun MS, Guerin A, et al. The economic burden of schizophrenia in the United States in 2013. J Clin Psychiatry 2016;77:764-71
   PubMed Web of Science ®Google Scholar
• Cloutier M, Greene M, Guerin A, et al. Total and excess costs associated with bipolar I disorder in the United States in 2015. Poster session presented at ASHP Summer Meetings and Exhibition; June 3–7, 2017; Minneapolis, MN.
   Google Scholar
• Olivares JM, Sermon J, Hemels M, et al. Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review. Ann Gen Psychiatry 2013;12:32
   PubMed Web of Science ®Google Scholar
• Lafeuille M-H, Gravel J, Lefebvre P, et al. Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics. J Med Econ 2013;16:1290-9
   PubMedGoogle Scholar
• Bergeson JG, Kalsekar I, Jing Y, et al. Medical care costs and hospitalization in patients with bipolar disorder treated with atypical antipsychotics. Am Health Drug Benefits 2012;5:379-86
   PubMedGoogle Scholar
• Almond S, Knapp M, Francois C, et al. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry J Ment Sci 2004;184:346-51
   PubMed Web of Science ®Google Scholar
• Awad AG, Voruganti LNP. The burden of schizophrenia on caregivers. PharmacoEconomics 2008;26:149-62
   PubMed Web of Science ®Google Scholar
• Suzuki T. A further consideration on long-acting injectable versus oral antipsychotics in the treatment of schizophrenia: a narrative review and critical appraisal. Expert Opin Drug Deliv 2016;13:253-64
   PubMed Web of Science ®Google Scholar
• Gigante AD, Lafer B, Yatham LN. Long-acting injectable antipsychotics for the maintenance treatment of bipolar disorder. CNS Drugs 2012;26:403-20
   PubMed Web of Science ®Google Scholar
• Brissos S, Veguilla MR, Taylor D, et al. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol 2014;4:198-219
   PubMedGoogle Scholar
• Wu C-S, Hsieh MH, Tang C-H, et al. Comparative effectiveness of long-acting injectable risperidone vs. long-acting injectable first-generation antipsychotics in bipolar disorder. J Affect Disord 2016;197:189-95
   PubMed Web of Science ®Google Scholar
• Otsuka Pharmaceuticals Co., Ltd and H. Lundbeck A/s. Abilify Maintena® (aripiprazole) for extended-release injectable suspension approved by the U.S. FDA for maintenance monotherapy treatment of bipolar I disorder. 2017. Valby, Denmark and Tokyo, Japan. Available online at: http://investor.lundbeck.com/releasedetail.cfm?releaseid =1034936. Accessed August 2, 2017
   Google Scholar
• Lehman A, Lieberman J, Dixon L, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161:1-56
   PubMed Web of Science ®Google Scholar
• Moore LA, Kaufman MD, Algozzine R, et al. Adherence to therapy: using an evidence-based protocol. Rehabil Nurs 2007;32:227-32
   PubMed Web of Science ®Google Scholar
• Correll CU, Citrome L, Haddad PM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry 2016;77:1-24
   PubMed Web of Science ®Google Scholar
• Joshi K, Pan X, Wang R, et al. Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate. Curr Med Res Opin 2016;32:1873-81
   PubMed Web of Science ®Google Scholar
• Marcus SC, Zummo J, Pettit AR, et al. Antipsychotic adherence and rehospitalization in schizophrenia ptients receiving oral versus long-acting injectable antipsychotics following hospital discharge. J Manag Care Spec Pharm 2015;21:754-68
   PubMed Web of Science ®Google Scholar
• Wu EQ, Shi L, Birnbaum H, et al. Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach. Psychol Med 2006;36:1535
   PubMed Web of Science ®Google Scholar
• Khaykin E, Eaton W, Ford D, et al. Health insurance coverage among persons with schizophrenia in the United States. Psychiatr Serv 2010;61:830-4
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
   PubMedGoogle Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
   PubMed Web of Science ®Google Scholar
• HCUP Chronic Condition Indicator [Internet]. Rockville, MD: Agency for Healthcare Research and Quality; 2015. Available online at: www.hcup-us.ahrq.gov/toolssoftware/chronic/chronic.jsp. Accessed March 2, 2017
   Google Scholar
• Emsley R, Chiliza B, Asmal L, et al. The nature of relapse in schizophrenia. BMC Psychiatry 2013;13:50
   PubMed Web of Science ®Google Scholar
• Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol 2013;132:101-9
   PubMed Web of Science ®Google Scholar
• Kamat S, Offord S, Docherty J, et al. Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients. Drugs Context 2015;4:1-12
   Google Scholar
• Rossi G, Frediani S, Rossi R, et al. Long-acting antipsychotic drugs for the treatment of schizophrenia: use in daily practice from naturalistic observations. BMC Psychiatry 2012;12:122
   PubMed Web of Science ®Google Scholar
• Kane JM, Kim E, Kan HJ, et al. Comparative utility of aripiprazole and haloperidol in schizophrenia: post hoc analysis of two 52-week, randomized, controlled trials. Appl Health Econ Health Policy 2009;7:109-19
   PubMedGoogle Scholar
• Koola MM, Wehring HJ, Kelly DL. The potential role of long-acting injectable antipsychotics in people with schizophrenia and comorbid substance use. J Dual Diagn 2012;8:50-61
   PubMed Web of Science ®Google Scholar
• Kirschner M, Theodoridou A, Fusar-Poli P, et al. Patients’ and clinicians’ attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis. Ther Adv Psychopharmacol 2013;3:89-99
   PubMedGoogle Scholar
• Potkin S, Bera R, Zubek D, et al. Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia. BMC Psychiatry 2013;13:261
   PubMed Web of Science ®Google Scholar
• Sacchetti E, Grunze H, Leucht S, et al. Long-acting injection antipsychotic medications in the management of schizophrenia. Evid-Based Psychiatr Care 2015;1:27-36
   Google Scholar
• Pandina G, Lane R, Gopal S, et al. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:218-26
   PubMed Web of Science ®Google Scholar
• Li H, Rui Q, Ning X, et al. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. Suicide Suicidal Behav 2011;35:1002-8
   Google Scholar
• Naber D, Hansen K, Forray C, et al. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia. Schizophr Res 2015;168:498-504
   PubMed Web of Science ®Google Scholar